Amyloidosis trials in Spain

In Spain 25 Also abroad 185

15 of 25 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Where
A Coruña, Barcelona, L'hospitalet De Llobregat, Madrid, Málaga, Palma, Pamplona, Salamanca
Age
18 years to 90 years
People
1,200 worldwide
Run by
Intellia Therapeutics
See details and how to joinNCT06128629 · EU 2023-507220-23-00
Phase 1Taking people
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Where
Badalona, Barcelona, Madrid, Pamplona, Salamanca
Age
18 years and over
People
180 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00
Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
Where
Barcelona, Gijón, Málaga, Pamplona, Salamanca
Age
18 years to 64 years
People
60 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07224672 · EU 2025-522803-60-00
Phase 3Enrolling by invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
Barcelona, Bilbao, L'Hospitalet de Llobregat, Madrid, Málaga
Age
18 years and over
People
700 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT06679946
Phase 3Taking people
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Where
A Coruña, Badalona, Barcelona, Bilbao, Córdoba, Donostia / San Sebastian, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Palma de Mallorca, Santiago de Compostela, Seville, Úbeda, Valencia, Zaragoza
Age
18 years and over
People
1,280 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07207811
Phase 3Taking people
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
A Coruna, Barcelona, Bilbao, Huelva, Jaén, L'hospitalet De Llobregat, Lleida, Madrid, Majadahonda, Murcia, Palma, Pamplona, Salamanca, Santiago De Compostela, Valencia, Vigo
Age
18 years to 85 years
People
1,750 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00
Phase 3Taking people
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Where
Barcelona, Huelva, L'hospitalet De Llobregat, Madrid, Palma
Age
18 years to 85 years
People
125 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07223203 · EU 2025-522544-40-00
Phase 1Taking people
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Where
Barcelona, Salamanca
Age
18 years and over
People
276 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06768489 · EU 2024-515316-44-00
Phase 3Not yet taking people in Spain
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
Where
A Coruña, Barcelona, El Palmar, Jaén, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Palma de Mallorca, Pamplona, Salamanca, Santiago de Compostela-Coru A, Valencia
People
1,180 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00
Phase 1/2Taking people
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Where
Barcelona, Gijón, Madrid, Móstoles, Murcia, Palma, Pamplona, Valencia
Age
18 years and over
People
220 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06292780 · EU 2023-507809-34-00
Phase 3Not yet taking people in Spain
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
Where
A Coruña, Huelva, L'hospitalet De Llobregat, Majadahonda, Palma, Salamanca
Age
18 years and over
People
250 worldwide
Run by
Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT07116473 · EU 2024-513676-18-00
Phase 3Taking people
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Where
A Coruna, Huelva, L'hospitalet De Llobregat, Majadahonda, Palma, Salamanca
Age
18 years to 75 years
People
587 worldwide
Run by
Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895 · EU 2024-513547-82-00
Phase 4Taking people
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
Where
Huelva, L'hospitalet De Llobregat, Majadahonda, Palma, Salamanca
Age
18 years to 80 years
People
150 worldwide
Run by
Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT07695701 · EU 2026-526068-19-00
Phase 3Enrolling by invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Where
Barcelona, Majadahonda, Murcia, Santiago de Compostela
Age
18 years and over
People
1,400 worldwide
Run by
Ionis Pharmaceuticals, Inc.
See details and how to joinNCT05667493
Phase 3Not yet taking people in Spain
Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction
Where
A Coruña, Barcelona, Ciudad Real, Donostia, L'hospitalet De Llobregat, Majadahonda, Salamanca, Santiago de Compostela, Zaragoza
Age
18 years and over
People
114
Run by
Puerta de Hierro University Hospital
See details and how to joinNCT06712030 · EU 2024-515661-34-00